Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05020652CT.gov A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Myelofibrosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| tq05105 tablets (this asset) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P2 | B · 57 |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
| Nivestim | City of Hope Medical Center | P3 | B |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | Fred Hutchinson Cancer Center | P2/3 | B |
| Alemtuzumab | University of Arizona | P2/3 | B |
| Fludarabine | Center for International Blood and Marrow Transplant Research | P3 | B |
| Cyclosporin A | City of Hope Medical Center | P2 | B |
| Busulfanum | City of Hope Medical Center | P2 | B |
| Melphalan | Center for International Blood and Marrow Transplant Research | P2 | B |
+42 more in the Myelofibrosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. tq05105 tablets in Myelofibrosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tq05105-tablets-myelofibrosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →